Tissue-based PEG10 expression as an exploratory biomarker associated with first-line R-CHOP treatment outcome in diffuse large B-cell lymphoma. (PubMed, Future Oncol) - Oct 7, 2026 - "Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma, and 30-40% of patients develop primary resistance to first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Tissue PEG10 overexpression is associated with adverse clinicopathological features and unfavorable R-CHOP response and may serve as an exploratory complementary tissue-based biomarker in DLBCL. These findings require validation in larger prospective multicenter cohorts before clinical implementation in practice."
Biomarker • Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin's Lymphoma • Oncology
|
|
Dina I Hemdan; Haidan M El-Shorbagy; Lobna Ezz El-Arab; Mohamed Alorabi; Nashwa El-Khazragy; Salwa Sabet
|